AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 151 min read$TEM

Tempus AI, Inc. (TEM) Sets Q3 2026 Results for Nov. 2

Tempus AI, Inc. (TEM) will release Q3 2026 earnings on Nov. 2, 2026, before market open, followed by a webcast at 8:45 a.m. ET. The company has not yet provided specific financial guidance or updates.

Original reporting
tradingview.com
Published Oct 15, 2026, 8:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 15, 2026, 8:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Tempus AI, Inc. (TEM) Sets Q3 2026 Results for Nov. 2 — source image
Source · tradingview.com
Decision brief

The 30-second read

$TEMNeutralMed
01

Why it matters

Traders can use the disclosed timing to plan orders, hedges, and volatility exposure into the Nov. 2 pre-market release, but the text does not provide new fundamentals that would justify a directional thesis yet.

02

Market read

Useful for event timing and risk management ahead of the Q3 2026 earnings release, with no new financial information provided.

03

What to watch

The real trading signal will come from any new guidance, margin commentary, or material business updates delivered during the webcast, none of which are included here.

Relevance 4/10Novelty 3/10Timing: ahead of Q3 2026 results on Nov. 2 before the U.S. market open

Background

The article is a routine earnings scheduling notice for Tempus AI’s Q3 2026 results and webcast.

Company-level read

Ticker impact

$TEMNeutralMedium confidence
Context

Tempus AI schedules Q3 2026 results for Nov. 2 before U.S. markets open and a webcast at 8:45 a.m. ET.

Expected impact

Likely modest pre-event volatility as traders position for the upcoming earnings release, with direction dependent on the actual Q3 results and any guidance on the call.

Evidence & confidence

The article only discloses timing (release date and webcast time) and does not provide financial results, guidance, or other new fundamentals.

Market effects

Sector

Limited sector read-through because the piece provides no performance metrics or guidance.

Regional

Primarily affects U.S. small-to-mid cap growth/health-tech sentiment around the earnings window.

Global

Low, as the disclosure is a U.S.-time earnings schedule with no international operational details.

Counterpoint

What could challenge this read

Because the article is only a scheduling notice, it may not meaningfully change expectations versus what traders already infer from standard earnings calendars.

Key entities

  • company
    Tempus AI, Inc.

    Subject of the article, scheduled to report Q3 2026 results before the U.S. market open on Nov. 2, 2026 and host a webcast at 8:45 a.m. ET.

Read at source← All news

Related articles

OCT 26
$TEMMed

What Happens To Tempus AI Stock If Its Cash Burn Continues?

Tempus AI (TEM) expects positive free cash flow by year-end but had a $273M cash burn over the past year. With $816M in cash, the company's reserves could last about three years at current burn rates. Revenue grew 20% and 36% in diagnostics and data businesses, respectively. Management raised 2026 revenue guidance to $1.595B-$1.605B and issued $460M in convertible notes. The company plans to acquire Personalis, potentially using debt to fund the deal.

finance.yahoo.com2 min
OCT 26
$BMYMed

Pathos AI Announces Strategic Collaborations with Bristol Myers Squibb and Tempus AI to Advance AI-Driven Drug Development Beginning with Alzheimer’s Disease and Other Neurological Conditions

Pathos AI has partnered with Bristol Myers Squibb (BMY) and Tempus (TEM) to advance AI-driven drug development for Alzheimer’s and other neurological conditions. Tempus will create a dataset from hundreds of thousands of patients, which Pathos will license for $55 million over five years. BMY leads Pathos's Series E financing and gains access to Pathos's AI platform, Pathos Foundry, for its R&D portfolio, with exclusive rights in neuroscience for three years.

biospace.com3 min
OCT 24
$BMYMed

Tempus Sets $55 Million Ceiling for Pathos Neurology Data Contract

Tempus AI signed a five-year neurology data deal with Pathos AI, potentially worth $55 million. Tempus will deliver up to 500,000 records, with Pathos paying $100 per record. Bristol Myers Squibb gains nonexclusive Foundry access and three-year exclusive rights for neuroscience development. Tempus also has a $137.5 million oncology deal with BMS, totaling $192.5 million if both deals reach full value.

econotimes.com2 min
OCT 23
$TEMMed

Tempus AI Gains 6% as Bristol Myers Squibb Licenses Oncology Data

Tempus AI shares rose 6% after Bristol Myers Squibb agreed to a multi-year deal to license its oncology data through 2031. Tempus's data and AI platform will support BMS's drug discovery and development. Data licensing is Tempus's most profitable segment, with 36% revenue growth in Q2. The financial terms of the deal were not disclosed.

finance.yahoo.com2 min